Analogix Introduces Times Square Reference Design RD1011, Industry’s First Bi-directional USB-C Active Cable With Integrated Retimer
6.1.2020 17:15:00 EET | Business Wire | Press release
Analogix Semiconductor, Inc. today announced the availability of Times Square RD1011, its high-performance reference design for USB-C™ to USB-C™ active cable with true bi-directional support, capable of connecting a USB-C source to a USB-C device across multi-meter distances.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106005248/en/
Analogix's Times Square RD1011 bi-directional USB-C active cable with Integrated retimer (Graphic: Business Wire)
Leveraging Analogix’s expertise in high-speed signal management, USB-C port controller architecture, and proven SRIS and LTTPR retimer technology, RD1011 offers best-in-class performance with highest interoperability, lowest power consumption at under 1.5W, and lowest bill of materials (BOM) cost featuring:
- Dual retimer architecture with connection via a 4 meter twisted-pair cable and one paddle card at each end of the cable to maximize length without sacrificing performance;
- Bi-directional solution for extending USB-C, USB 3.2 10 Gbps Gen2 or DisplayPort 8.1 Gbps HBR3 source output over long distances;
- SRIS architecture for true USB 3.2 compliance, as well as transparent and non-transparent (LTTPR) architecture for DisplayPort 1.4a interoperability;
- Fully functional e-marker controller with Power Deliver (PD 3.0) handling USB-C power contract negotiation and SOP`/SOP`` messages.
“We’re pleased to be further expanding our industry-leading signal conditioning technology to pertinent and fundamental applications,” said Michael Ching, vice president of marketing at Analogix. “Times Square’s clever architecture will extend the system performance across a thin and powerful USB-C cable to display monitors, highly integrated docking stations, and VR HMDs.”
“We see growing demand for USB 3.2 USB-C to USB-C active cables and Analogix’s reference design is the framework that enables such connections with optimal performance,” said Robert Lin, Head of ABG US Sales and Support at Foxlink.
RD1011 is sampling now and product demonstrations are taking place during this week’s CES® 2020, at Analogix Exhibitor Suite 30-136 in The Venetian, Las Vegas.
About Analogix Semiconductor
Analogix Semiconductor, Inc. designs and manufactures semiconductors for the digital multimedia market, from portable devices such as smartphones, notebooks, and AR/VR head mounted displays, to large, high-definition TVs and high-end graphics cards. Analogix is the market leader in providing end-to-end interface connectivity semiconductor solutions for DisplayPort under its SlimPort brand, including high-speed signal conditioners, and an industry leader in display panel controllers, such as low-power, high-speed timing controller solutions. The DisplayPort standard is an innovative, packetized digital interface for high-resolution video and audio that was developed by the Video Electronics Standards Association (VESA). SlimPort branded products are compliant with DisplayPort, Mobility DisplayPort (MyDP), and DisplayPort Alternate Mode over the USB Type-C connector.
Analogix display panel timing controllers offer the world’s lowest power, smallest packaging, and proprietary image enhancement to produce more accurate colors, thinner bezels, and smoother frame rates on the latest high dynamic range (HDR) panels.
For more information visit www.analogix.com and www.slimport.com, follow us on Twitter @Analogix and @SlimPortConnect, or connect with us on LinkedIn.
Analogix and SlimPort are trademarks or registered trademarks of Analogix Semiconductor, Inc. All other trademarks and trade names are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106005248/en/
Contact information
Analogix Media Contact
Gratia Stefan
Tel: 408-988-8848
marcom@analogix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom